SynthesisClinical rheumatology2008
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence.
Synthesis in Clinical rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis.The Cochrane database of systematic reviews · 2025Pooled it
- Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.Rheumatology (Oxford, England) · 2021Pooled it
- The clinical effectiveness of intra-articular corticosteroids for arthritis of the lower limb in juvenile idiopathic arthritis: a systematic review.Pediatric rheumatology online journal · 2014Pooled it
- Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Adherence in young people living with juvenile arthritis: A systematic review.Clinical practice in pediatric psychology · 2024Article
- Application of Intra-articular Corticosteroid Injection in Juvenile Idiopathic Arthritis.Frontiers in pediatrics · 2022Review
- Knee Acoustic Emissions as a Digital Biomarker of Disease Status in Juvenile Idiopathic Arthritis.Frontiers in digital health · 2020Article
- Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2019Article
- USG Doppler in Juvenile Idiopathic Arthritis Treatment Response Assessment: A Much Needed Objective Tool.Indian journal of pediatrics · 2017Article
- Implant survival and radiographic outcome of total hip replacement in patients less than 20 years old.Acta orthopaedica · 2016Article
- Effect of untreated and treated temporomandibular joint arthritis on mandibular volume development in growing rabbits.Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie · 2015Article
- Etanercept biosimilars.Rheumatology international · 2015Review
- Treatment of systemic-onset juvenile arthritis with canakinumab.Open access rheumatology : research and reviews · 2015Review
- A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases.European journal of rheumatology · 2014Article
- Adalimumab for juvenile idiopathic arthritis-associated uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Article
- Pain experience in children with juvenile idiopathic arthritis treated with anti-TNF agents compared to non-biologic standard treatment.Pediatric rheumatology online journal · 2013Article
- Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.BioMed research international · 2013Review
- Youth report of healthcare transition counseling and autonomy support from their rheumatologist.Pediatric rheumatology online journal · 2012Article
- Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Paediatric drugs · 2011Review
- Off-label use of rituximab in a multipayer insurance system.Journal of oncology practice · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologics are an important therapeutic option for treating patients with juvenile idiopathic arthritis (JIA). In adults, they are associated with rare but severe adverse events such as serious infections and malignancies. We reviewed systematically the evidence on the efficacy and safety of biologics for the treatment of JIA. We searched electronic databases up to August 2006. We limited evidence to prospective studies for efficacy but included retrospective observational evidence for safety. Outcomes of interest were clinical response, radiographic progression, quality of life, and adverse events. One randomized controlled trial (RCT) and 11 uncontrolled prospective studies provided data on efficacy; three additional studies assessed safety. The only RCT and six uncontrolled trials support the general efficacy of etanercept for the treatment of JIA. Internal and external validity of these studies are limited. The evidence on other biologic agents such as adalimumab, abatacept, anakinra, infliximab, rituximab, and tocilizumab is sparse or entirely missing. Because of the lack of sound long-term safety data, evidence is insufficient to draw firm conclusions about the balance of risks and benefits of any biologic agent for the treatment of JIA. Clinicians have to be aware of the lack of evidence supporting a long-term net benefit when considering biologics for patients with JIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.